Stock listing
CVKD Stock Price, News, Filings & Events — Cadrenal Therapeutics, Inc.
Selected listing: CVKD · NASDAQ · USD · US
This page tracks Cadrenal Therapeutics, Inc.'s CVKD:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following CVKD:NASDAQ. CVKD:NASDAQ is the stock-level entry point for investors researching Cadrenal Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Cadrenal Therapeutics, Inc. (ticker: CVKD) is a public company operating in the American market, with a market capitalization of approximately $6.7 million. The company focuses on developing innovative therapies to address unmet medical needs. Investors can find more information about its operations and market presence on its dedicated company page.
- Ticker
- CVKD:NASDAQ
- Asset type
- Stock
- Market cap
- $4.4M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Cadrenal Therapeutics, Inc. CVKD:NASDAQ stock context
This page tracks Cadrenal Therapeutics, Inc.'s CVKD:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following CVKD:NASDAQ. CVKD:NASDAQ is the stock-level entry point for investors researching Cadrenal Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Cadrenal Therapeutics, Inc. (ticker: CVKD) is a public company operating in the American market, with a market capitalization of approximately $6.7 million. The company focuses on developing innovative therapies to address unmet medical needs. Investors can find more information about its operations and market presence on its dedicated company page.
Latest news from Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
September 3, 2026
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Th...
August 31, 2026
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franc...
August 13, 2026
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following La...
July 21, 2026
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 1...
July 13, 2026
Research Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for CVKD:NASDAQ.
Cadrenal Therapeutics, Inc. company profile
View the public company page for Cadrenal Therapeutics, Inc. on 6ix.
Cadrenal Therapeutics, Inc. news
Read company news and market updates connected to Cadrenal Therapeutics, Inc..
Cadrenal Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Cadrenal Therapeutics, Inc..